Lineage Cell Therapeutics Ratios (2010-2026) | LCTX

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Ratios	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Profitability
Gross Margin (Quarter)	75.59%	56.61%	1.93%	96.64%	95.28%	92.16%	94.67%	95.01%	96.06%	86.44%	87.74%	93.21%	96.88%	98.99%	94.63%	97.60%	98.59%	99.86%	99.00%	100.00%
EBT Margin (Quarter)	-969.73%	-389.69%	-56.02%	-135.44%	-148.96%	-185.96%	-332.22%	-260.14%	-161.33%	-574.48%	-225.77%	-454.16%	-410.01%	-79.41%	-113.32%	-401.26%	-698.95%	-92.91%	244.66%	-416.70%
EBIT Margin (Quarter)	-1,382.81%	-301.45%	-56.48%	-122.13%	-92.99%	-175.15%	-346.68%	-278.37%	-155.78%	-538.12%	-304.69%	-461.29%	-416.69%	-101.61%	-178.17%	-433.09%	-715.37%	-102.85%	238.71%	-440.17%
EBITDA Margin (Quarter)	-1,382.81%	-301.45%	-56.48%	-122.13%	-92.99%	-175.15%	-346.68%	-278.37%	-155.78%	-538.12%	-304.69%	-461.29%	-416.69%	-101.61%	-178.17%	-433.09%	-715.37%	-102.85%	238.71%	-440.17%
Operating Margin (Quarter)	-1,382.81%	-301.45%	-56.48%	-122.13%	-92.99%	-175.15%	-346.68%	-278.37%	-155.78%	-538.12%	-304.69%	-461.29%	-416.69%	-101.61%	-178.17%	-433.09%	-715.37%	-102.85%	238.71%	-440.17%
Net Margin (Quarter)	-969.73%	-345.11%	-56.02%	-135.44%	-148.96%	-185.96%	-332.22%	-184.58%	-161.33%	-574.48%	-225.77%	-454.16%	-410.01%	-79.41%	-113.32%	-401.26%	-698.95%	-92.91%	244.66%	-278.96%
FCF Margin (Quarter)	-1,083.01%	-215.95%	-12.04%	417.38%	-157.24%	-192.33%	-412.64%	-479.04%	-202.29%	-369.26%	-320.16%	-403.12%	-369.03%	-156.89%	-234.00%	-331.76%	-200.83%	-95.90%	-81.34%	-472.35%
Efficiency
Inventory Average (Quarter)
Assets Average (Quarter)	131.34M	132.98M	152.88M	159.53M	140.22M	133.53M	127.41M	118.43M	112.45M	108.92M	103.59M	104.75M	105.64M	99.70M	104.91M	112.49M	101.28M	90.22M	101.11M	111.06M
Equity Average (Quarter)	120.09M	121.59M	105.24M	88.06M	83.36M	79.53M	74.74M	70.48M	70.14M	68.96M	64.34M	66.51M	68.93M	65.83M	70.90M	77.33M	62.38M	34.58M	32.69M	48.61M
Invested Capital (Quarter)	123.63M	119.62M	90.93M	85.28M	81.55M	77.59M	72.05M	69.20M	71.42M	66.81M	62.02M	70.99M	66.88M	64.79M	77.01M	77.66M	47.11M	22.04M	43.35M	53.88M
Asset Utilization Ratio (Quarter)	0.01	0.03	0.35	0.36	0.44	0.47	0.12	0.10	0.09	0.08	0.09	0.08	0.06	0.09	0.09	0.08	0.11	0.12	0.14	0.13
Leverage & Solvency
Debt to Equity (Quarter)
Debt Ratio (Quarter)
Equity Ratio (Quarter)	0.92	0.91	0.52	0.59	0.60	0.59	0.58	0.61	0.64	0.63	0.61	0.65	0.65	0.67	0.68	0.69	0.52	0.25	0.39	0.49
Valuation
Enterprise Value (Quarter)	-69.86M	-66.23M	-59.68M	-81.27M	-73.38M	-67.75M	-59.28M	-48.25M	-47.33M	-42.79M	-36.89M	-45.03M	-39.92M	-34.10M	-44.40M	-49.28M	-36.97M	-33.49M	-62.16M	-63.90M
Return Ratios
Return on Sales (Quarter)	-0.10%	-0.03%	-0.01%	-0.01%	-0.01%	-0.02%	-0.03%	-0.02%	-0.02%	-0.06%	-0.02%	-0.05%	-0.04%	-0.01%	-0.01%	-0.04%	-0.07%	-0.01%	0.02%	-0.04%
Return on Capital Employed (Quarter)	-21.46%	-21.62%	-46.53%	-35.98%	-39.70%	-39.82%	-20.77%	-22.49%	-24.44%	-26.88%	-28.88%	-28.17%	-28.32%	-26.48%	-23.62%	-21.45%	-38.93%	-43.52%	-15.93%	-14.95%
Return on Invested Capital (Quarter)		0.00%					0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (Quarter)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (Quarter)	0.00%	0.00%	0.00%	-0.01%	-0.01%	-0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.01%	-0.01%	0.00%	0.00%

Research Tools

Developers

Lineage Cell Therapeutics Ratios (2010-2026) | LCTX

Research Tools

Developers

Lineage Cell Therapeutics Ratios (2010-2026) | LCTX

Create an account

Sign In

Reset Password